Risk for T2DM Increased With Use of 5α-Reductase Inhibitors
Increased risk seen among men using dutasteride, finasteride for benign prostatic hyperplasia
Endocrine Disorders
Atrasentan Tied to Lower Risk for Kidney Events in T2DM With CKD
Atrasentan is associated with a reduced risk for renal events in patients with type 2 diabetes and chronic kidney disease.
Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
But no significant differences seen in gestational DM risk between metformin users, nonusers.
Canagliflozin Lowers ESRD Risk in Diabetic Kidney Disease
Canagliflozin decreases the risk of kidney failure in patients with chronic kidney disease and type 2 diabetes, according to a new study.
Sanofi Expands Savings Program to Include More Insulin Pens, Vials at Set Monthly Price
Sanofi announced plans to expand its ‘insulins Valyou Savings Program’ that will further reduce the cost of Sanofi insulins for patients with diabetes. The Insulins Valyou Savings Program was launched a year ago to set the price for cash-paying patients at $99 for one 10mL vial or $149 for one box of pens. Now, the…
Topical Corticosteroids Associated With Higher Risk for Type 2 Diabetes
Dose-response relationship observed in large European cohort
FDA Rejects NDA for Gastroparesis Treatment Gimoti
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Evoke Pharma regarding the New Drug Application (NDA) for Gimoti (metoclopramide nasal spray).
Real-World Study Data Comparing Empagliflozin vs DPP-4 Inhibitors
Boehringer Ingelheim and Lilly announced preliminary data from the EMPRISE ( EMPagliflozin compaRative effectIveness and SafEty) real-world study at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2019 in San Diego.
Invokana sNDA Seeking Treatment of Chronic Kidney Disease in T2D Patients
Janssen announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of end-stage renal disease and renal or cardiovascular (CV) death in adults with type 2 diabetes and chronic kidney disease.
ADA Issues Updates to Standards of Medical Care in Diabetes
The American Diabetes Association (ADA) has updated the Standards of Medical Care in Diabetes for 2019 based on recently published research.
